

# Curtis Triplitt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10956058/publications.pdf>

Version: 2024-02-01

28  
papers

1,424  
citations

361413

20  
h-index

501196

28  
g-index

28  
all docs

28  
docs citations

28  
times ranked

2335  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (<sc>EDICT</sc>). Diabetes, Obesity and Metabolism, 2022, 24, 899-907.	4.4	15
2	Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose. Diabetes Care, 2022, 45, 1372-1380.	8.6	4
3	Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. Diabetes Care, 2021, 44, 433-439.	8.6	29
4	Therapeutic Manipulation of Myocardial Metabolism. Journal of the American College of Cardiology, 2021, 77, 2022-2039.	2.8	40
5	Insulin secretion is a strong predictor for need of insulin therapy in patients with new-onset diabetes and <sc>HbA1c of more than 10%: A</sc> post hoc analysis of the <sc>EDICT</sc> study. Diabetes, Obesity and Metabolism, 2021, 23, 1631-1639.	4.4	2
6	Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin. Diabetes Care, 2020, 43, 2519-2527.	8.6	3
7	Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3226-3233.	3.6	10
8	Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors. Diabetes, 2020, 69, 681-688.	0.6	23
9	Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes. Diabetes Care, 2020, 43, 1234-1241.	8.6	30
10	Empagliflozin Treatment Is Associated With Improved $\beta$ -Cell Function in Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1402-1407.	3.6	63
11	Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy. Diabetes, 2018, 67, 1182-1189.	0.6	44
12	Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care, 2017, 40, 325-331.	8.6	32
13	Determinants of the increase in ketone concentration during <sc>SGLT2</sc> inhibition in <sc>NGT</sc>, <sc>IFG</sc> and <sc>T2DM</sc> patients. Diabetes, Obesity and Metabolism, 2017, 19, 809-813.	4.4	61
14	Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes. Diabetes, 2017, 66, 1999-2006.	0.6	67
15	Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves $\beta$ -Cell Function in Subjects With Impaired Fasting Glucose. Diabetes, 2017, 66, 2495-2502.	0.6	21
16	Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. Hepatology, 2016, 64, 2028-2037.	7.3	78
17	Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System. Diabetes, 2015, 64, 3406-3412.	0.6	45
18	Assessment of Pancreatic $\beta$ -Cell Function: Review of Methods and Clinical Applications. Current Diabetes Reviews, 2014, 10, 2-42.	1.3	179

#	ARTICLE	IF	CITATIONS
19	Acute insulin resistance stimulates and insulin sensitization attenuates vascular smooth muscle cell migration and proliferation. <i>Physiological Reports</i> , 2014, 2, e12123.	1.7	10
20	Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2756-2762.	8.6	52
21	Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. <i>Vascular Health and Risk Management</i> , 2010, 6, 671.	2.3	17
22	Effects of Exenatide Plus Rosiglitazone on $\beta$ -Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin. <i>Diabetes Care</i> , 2010, 33, 951-957.	8.6	100
23	Addition of Pioglitazone and Ramipril to Intensive Insulin Therapy in Type 2 Diabetic Patients Improves Vascular Dysfunction by Different Mechanisms. <i>Diabetes Care</i> , 2008, 31, 121-127.	8.6	53
24	Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008, 294, E846-E852.	3.5	144
25	Exenatide: From the Gila Monster to the Pharmacy. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2006, 46, 44-55.	1.5	41
26	Incretin Mimetics and Dipeptidyl Peptidase-IV Inhibitors: Potential New Therapies for Type 2 Diabetes Mellitus. <i>Pharmacotherapy</i> , 2006, 26, 360-374.	2.6	33
27	Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus. <i>Expert Review of Endocrinology and Metabolism</i> , 2006, 1, 329-341.	2.4	21
28	Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002, 283, E1135-E1143.	3.5	207